WTA and Stats Perform Serve up Breakthrough Tennis AI and Data Partnership, in Landmark Deal for Women’s Sports
The WTA (Women’s Tennis Association) today named Stats Perform its Official WTA Data Supplier.
The transformative partnership will deliver multiple feeds to customers - an exclusive umpire-derived data feed for an expanded number of WTA matches, as well as an ultrafast data feed collected by Stats Perform’s Opta analysts.
The data collected by Stats Perform’s Opta analysts will include detailed match statistics down to rally and shot level. This will dramatically increase the level of live insight available for thousands of WTA matches to power a new range of broadcast, second screen, and betting experiences.
The data feed will support Stats Perform’s advanced AI capabilities which will be leveraged to help bring fans closer to the sport through engaging data-driven insights and stories. Through these unique insights, fans will be able to get to know the players and the game at a much deeper level.
The data also enhances Stats Perform’s existing live WTA video streaming service to help create the ultimate experience in trusted and entertaining in-play betting.
Stats Perform’s extensive sports content distribution capabilities will improve the availability of official WTA data to make it more accessible for authorized sportsbooks, broadcasters, OTT, media, sponsors, tech and fantasy games, giving fans and bettors fast, detailed and accurate tennis data.
As evidence of Stats Perform’s commitment to growing the profile of women athletes, the partnership will push more innovative insights and content to raise the profile of WTA players. The agreement also aims to elevate the betting experience through the delivery of faster, deeper feeds, and promote integrity in tennis via the provision of two operationally independent feeds.
Carl Mergele, CEO Stats Perform, says: “The WTA has very ambitious goals for their tournaments and players and we’re proud to be trusted to help them reach new levels of fan and bettor engagement. Our broadcaster, media, and betting networks are already excited because they’ve seen how high-quality information elevates sport’s appeal.”
Micky Lawler, WTA President, says: “Stats Perform has a history of creating innovative and trusted content and products that drive entertainment levels and new revenue streams for the professional sports ecosystem. We’re looking forward to discovering new and unique storylines surrounding the WTA Tour and our players and tournaments available in new, exciting and comprehensive ways.”
Atop its sports AI and content expertise and customer network, Stats Perform’s globally famous and trusted Opta data brand has helped it transform the way fans and bettors interact with men’s and women’s soccer, cricket, rugby, basketball, NFL and MLB. The company has a long history of challenging how sport is measured, giving players, teams and leagues a competitive edge and broadcasters, media, sportsbooks and sponsors new perspectives. Women’s tennis is now also set to see a rise in the profile of and engagement with the Tour and its players.
About Stats Perform
Stats Perform is the market leader in SportsTech providing the most trusted sports data and the latest advancements in applying AI and machine learning to deliver better predictions for teams, sportsbooks and a more engaging broadcast, media and fan experience. The company collects the most detailed sports data to create new experiences across sports. Leveraging the richest sports database, Stats Perform enhances sports competition and entertainment through machine learning and computer vision to create advanced predictions and analysis – be that for digital and broadcast media with differentiated storytelling, tech companies with reliable and fast data to power their innovations, sportsbooks with in-play betting and integrity services, or teams with first-of-its-kind AI analysis software. SportsContentCo is the exclusive reseller of Stats Perform premium sports betting content to licensed sportsbooks in the United States. For more information, visit StatsPerform.com or SportsContentCo.com.
About WTA
Founded by Billie Jean King in 1973 on the principle of equal opportunity for women in sports, the WTA is the global leader in women’s professional sport with more than 1,650 players representing 84 nations competing for a record $180 million in prize money. In 2019, the WTA was watched by a record-breaking global audience of 700 million. The 2020 WTA Tour includes 53 events and four Grand Slams, spanning across six continents and 28 countries and regions. The season culminates with the Shiseido WTA Finals Shenzhen, offering a $14 million total prize purse and honoring the season’s top singles and doubles players. Further information on the WTA can be found at www.wtatennis.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005368/en/
Contact information
Sarah Butler, Stats Perform PR Manager
Sarah.butler@statsperform.com / +44 07432631237
Amy Binder, WTA, abinder@wtatennis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 09:00:00 EEST | Press release
Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with confidence. This joint offering provides an end-to-end solution designed to meet evolving regulatory expectations, accelerate adoption
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 08:00:00 EEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 08:00:00 EEST | Press release
Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturing of vaccines and life-saving therapies, including monoclonal antibodies, and emerging modalities like cell and gene therapies. By localizing these capacities in Europe, Merck hopes to reduce cross-border dependencies for the company’s customers. “Ireland is a leading hub for biopharmaceutical manufacturing and innova
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 08:00:00 EEST | Press release
Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface skin cells stop performing at the same level, or “go to sleep,” causing fine lines, dehydration, and looser skin, in turn leading to skin looking and feeling less firm and more fragile.1 Skin Activator technology serves as a “wake-up call” to sleeping surface skin cells. The unique complex is powered by encapsulated CICA to help restore the skin’s moisture barrier to visibly plump and firm skin as well as microdosed mandelic acid to increase surface skin cell turnover to visibly reduce dull, uneven skin. In clinical trials, the Skin Activator Hydrating & Firming Lotion showed to be effective
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom